Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Mineralys Therapeutics (MLYS) to $48 from $52 and keeps a Buy rating on the shares. The firm, which is updating its model after Q1 earnings and catching up with management, says results were “largely incremental,” but highlights that Mineralys expects to have a pre-NDA meeting with the FDA in Q4 to ensure the agency and the company are aligned on expectations for the NDA package for lorundrostat.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- 3 Best Stocks to Buy Now, 5/14/2025, According to Top Analysts
- Strong Financial Position and Promising Clinical Results Support Buy Rating for Mineralys Therapeutics
- Positive Buy Rating for Lorundrostat Driven by Successful Trials and Future Potential
- Optimistic Buy Rating for Mineralys Therapeutics Driven by Strategic Developments and Upcoming Data Releases
- Mineralys Therapeutics Reports Strong Trial Results and Financial Growth